Publikationen

Dam, S., Tscherne, A., Engels, L., Sutter, G., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2025). Design and evaluation of a poly-epitope based vaccine for the induction of influenza A virus cross-reactive CD8 + T cell responses. Scientific Reports, 15, Article 10586. https://doi.org/10.1038/s41598-025-95479-9
Details anzeigen

Guilfoyle, K., Mirolo, M., van, van der, Lombardo, M. S., Störk, T., Rimmelzwaan, G., Ludlow, M., & Osterhaus, A. (2025). Susceptibility of calf lung slice cultures to H5N1 influenza virus. Emerging Microbes & Infections, 14(1), Article 2432368. https://doi.org/10.1080/22221751.2024.2432368
Details anzeigen

Guilfoyle, K., Mirolo, M., de Waal, L., van Amerongen, G., van der Net, G., Störk, T., Lombardo, M. S., Baumgärtner, W., Bjarnason, Á., Jóhannsdóttir, H. B., Rimmelzwaan, G. F., Ludlow, M., & Osterhaus, A. D. M. E. (2025). Highly pathogenic avian influenza virus A/H5N1 subclade 2.3.4.4 b isolated from a European grey seal (Halichoerus grypus) is highly virulent in ferrets. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf348
Details anzeigen

Quiñones-Parra, S. M., Gras, S., Nguyen, T. H. O., Farenc, C., Szeto, C., Rowntree, L. C., Chaurasia, P., Sant, S., Boon, A. C. M., Jayasinghe, D., Rimmelzwaan, G. F., Petersen, J., Doherty, P. C., Uldrich, A. P., Littler, D. R., Rossjohn, J., & Kedzierska, K. (2025). Molecular determinants of cross-strain influenza A virus recognition by αβ T cell receptors. Science Immunology, 10(104), Article eadn3805. https://doi.org/10.1126/sciimmunol.adn3805
Details anzeigen

Agac, A., Meineke, R., Ludlow, M., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2024). RSV infection induces a proinflammatory immune response in primary monocytes. In 17th Graduate School Days: 22/23 November 2024 : abstract book (Zoo T 18). Stiftung Tierärztliche Hochschule Hannover.
Details anzeigen

Aregay, A., Slunečko, J., Korva, M., Bogovic, P., Resman Rus, K., Knap, N., Beicht, J., Kubinski, M., Saletti, G., Avšič-Županc, T., Steffen, I., Strle, F., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2024). Tick-borne encephalitis vaccine breakthrough infections induce aberrant T cell and antibody responses to non-structural proteins. Npj Vaccines, 9, Article 141. https://doi.org/10.1038/s41541-024-00936-7
Details anzeigen

Aregay, A., Slunečko, J., Bogovic, P., Korva, M., Resman Rus, K., Knap, N., Beicht, J., Kubinski, M., Saletti, G., Steffen, I., Strle, F., Avšič-Županc, T., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2024). Poor virus-specific T-cell responses early after tick-borne encephalitis virus infection correlate with disease severity. Emerging Microbes & Infections, 13(1), Article 2317909. https://doi.org/10.1080/22221751.2024.2317909
Details anzeigen

Aregay, A., Slunečko, J., Bogovic, P., Korva, M., Rus, K. R., Knap, N., Beicht, J., Kubinski, M., Saletti, G., Steffen, I., Sterle, F., Avšič-Županc, T., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2024). Poor virus-specific T-cell responses early after tick-borne encephalitis virus infection correlate with disease severity. In 8th World One Health Congress: abstract book (1089). https://globalohc.org/8WOHC
Details anzeigen

Kubinski, M., Beicht, J., Gerlach, T., Aregay, A., Osterhaus, A. D. M. E., Tscherne, A., Sutter, G., Prajeeth, C. K., & Rimmelzwaan, G. F. (2024). Immunity to tick-borne encephalitis virus NS3 protein induced with a recombinant modified vaccinia virus Ankara fails to afford mice protection against TBEV infection. Vaccines, 12(1), Article 105. https://doi.org/10.3390/vaccines12010105
Details anzeigen

Leroux-Roels, I., Prajeeth, K. C., Aregay, A., Nair, N., Rimmelzwaan, G. F., Osterhaus, A. D. M. E., Kardinahl, S., Pelz, S., Bauer, S., D’Onofrio, V., Alhatemi, A., Jacobs, B., De Boever, F., Porrez, S., Waerlop, G., Punt, C., Hendriks, B., von, van de, et al. (2024). Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against rift valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial. The Lancet: Infectious Diseases, 24(11), 1245–1253. https://doi.org/10.1016/S1473-3099(24)00375-X
Details anzeigen

Schweitzer, F., Letoha, T., Osterhaus, A., & Prajeeth, C. K. (2025). Impact of tick-borne orthoflaviviruses infection on compact human brain endothelial barrier. International Journal of Molecular Sciences, 26(5), Article 2342. https://doi.org/10.3390/ijms26052342
Details anzeigen

Schweitzer, F., Schröder, L.-J., Friedrichs, A., Gudi, V., Skripuletz, T., Steffen, I., Palus, M., Růžek, D., Osterhaus, A., & Prajeeth, C. K. (2025). Mosquito- and tick-borne orthoflaviviruses cross an in vitro endothelial-astrocyte barrier. Frontiers in Cellular and Infection Microbiology, 15, Article 1624636. https://doi.org/10.3389/fcimb.2025.1624636
Details anzeigen

Kubinski, M., Beicht, J., Gerlach, T., Aregay, A., Osterhaus, A. D. M. E., Tscherne, A., Sutter, G., Prajeeth, C. K., & Rimmelzwaan, G. F. (2024). Immunity to tick-borne encephalitis virus NS3 protein induced with a recombinant modified vaccinia virus Ankara fails to afford mice protection against TBEV infection. Vaccines, 12(1), Article 105. https://doi.org/10.3390/vaccines12010105
Details anzeigen

Leroux-Roels, I., Prajeeth, K. C., Aregay, A., Nair, N., Rimmelzwaan, G. F., Osterhaus, A. D. M. E., Kardinahl, S., Pelz, S., Bauer, S., D’Onofrio, V., Alhatemi, A., Jacobs, B., De Boever, F., Porrez, S., Waerlop, G., Punt, C., Hendriks, B., von, van de, et al. (2024). Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against rift valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial. The Lancet: Infectious Diseases, 24(11), 1245–1253. https://doi.org/10.1016/S1473-3099(24)00375-X
Details anzeigen

Nair, N., Chitappen Kandiyil, P., & Rimmelzwaan, G. F. (2024). Innate immune responses induced by attenuated Rift Valley Fever Virus (RVFV) infection in human PBMC. In 17th Graduate School Days: 22/23 November 2024 : abstract book (Zoo T 07). 17th Graduate School Days, 22.11.2024 – 23.11.2024. Stiftung Tierärztliche Hochschule Hannover.
Details anzeigen

Nair, N., Wichgers Schreur, P. J., Osterhaus, A. D. M. E., Rimmelzwaan, G. F., & Chittappen Kandiyil, P. (2024). Characterisation of innate immune responses induced by the Rift Valley Fever Virus (RVFV) in humans. International One Health Symposium 2024, 17.10.2024 - 19.10.2024.
Details anzeigen

Nair, N., Wichgers Schreur, P. J., Rimmelzwaan, G. F., Osterhaus, A. D. M. E., & Chittappen Kandiyil, P. (2024). Innate immune responses induced by Rift Valley Fever Virus (RVFV) infection in human PBMC. Conference title: 23rd Workshop Immunobiology of Viral Infections, 28.10.2024 ‒ 30.10.2024.
Details anzeigen

Prajeeth, C. K., Zdora, I., Saletti, G., Friese, J., Gerlach, T., Wilken, L., Beicht, J., Kubinski, M., Puff, C., Baumgärtner, W., Kortekaas, J., Wichgers Schreur, P. J., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2024). Immune correlates of protection of the four-segmented Rift Valley fever virus candidate vaccine in mice. Emerging Microbes & Infections, 13, Article 2373313. https://doi.org/10.1080/22221751.2024.2373313
Details anzeigen

Schweitzer, F., Schröder, L.-J., Gudi, V., Steffen, I., Palus, M., Růžek, D., Rimmelzwaan, G. F., Osterhaus, A. D. M. E., & Chittappen Kandiyil, P. (2024). From blood to brain: in vitro studies on orthoflavivirus neuroinvasion. In 17th Graduate School Days: 22/23 November 2024 : abstract book (ZSN T 06). Stiftung Tierärztliche Hochschule Hannover.
Details anzeigen

Beicht, J., Kubinski, M., Zdora, I., Puff, C., Biermann, J., Gerlach, T., Baumgärtner, W., Sutter, G., Osterhaus, A., Prajeeth, C. K., & Rimmelzwaan, G. F. (2023). Induction of humoral and cell-mediated immunity to the NS1 protein of TBEV with recombinant Influenza virus and MVA affords partial protection against lethal TBEV infection in mice. Frontiers in Immunology, 14, Article 1177324. https://doi.org/10.3389/fimmu.2023.1177324
Details anzeigen

Meineke, R., Stelz, S., Busch, M., Werlein, C., Kühnel, M., Jonigk, D., Rimmelzwaan, G. F., & Elbahesh, H. (2023). FDA-approved Abl/EGFR/PDGFR kinase inhibitors show potent efficacy against pandemic and seasonal influenza A virus infections of human lung explants. iScience, 26(4), Article 106309. https://doi.org/10.1016/j.isci.2023.106309
Details anzeigen

Meineke, R. (2022). Inhibition of Host Kinase Activity: Effects on Influenza A Virus Infection and Host Cell Signaling. https://nbn-resolving.org/urn:nbn:de:gbv:95-117384
Details anzeigen

Meineke, R., Stelz, S., Busch, M., Werlein, C., Kühnel, M., Jonigk, D., Rimmelzwaan, G. F., & Elbahesh, H. (2022). FDA-approved inhibitors of RTK/Raf signaling potently impair multiple steps of in vitro and ex vivo influenza A virus infections. Viruses, 14(9), Article 2058. https://doi.org/10.3390/v14092058
Details anzeigen

Becker, T., Elbahesh, H., Reperant, L. A., Rimmelzwaan, G. F., & Osterhaus, A. D. M. E. (2021). Influenza vaccines: successes and continuing challenges. The Journal of Infectious Diseases, 224(Supplement 4), 405–S419. https://doi.org/10.1093/infdis/jiab269
Details anzeigen

Palacios-Pedrero, M. Á., Osterhaus, A. D. M. E., Becker, T., Elbahesh, H., Rimmelzwaan, G. F., & Saletti, G. (2021). Aging and options to halt declining immunity to virus infections. Frontiers in Immunology, 12, Article 681449. https://doi.org/10.3389/fimmu.2021.681449
Details anzeigen

Ricke-Hoch, M., Stelling, E., Lasswitz, L., Gunesch, A. P., Kasten, M., Zapatero-Belinchón, F. J., Brogden, G., Gerold, G., Pietschmann, T., Montiel, V., Balligand, J.-L., Facciotti, F., Hirsch, E., Gausepohl, T., Elbahesh, H., Rimmelzwaan, G. F., Höfer, A., Kühnel, M. P., Jonigk, D., et al. (2021). Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease. PLoS ONE, 16(8), Article e0255335. https://doi.org/10.1371/journal.pone.0255335
Details anzeigen

Di, H., Elbahesh, H., & Brinton, M. A. (2020). Characteristics of human OAS1 isoform proteins. Viruses, 12(2: 152). https://doi.org/10.3390/v12020152
Details anzeigen

Meineke, R., Werlein, C., Kühnel, M., Jonigk, D., Rimmelzwaan, G. F., & Elbahesh, H. (2020). Differential susceptibility of pandemic H1N1 and seasonal H3N2 Influenza A viruses to clinically-approved small molecule kinase inhibitors. In Stiftung Tierärztliche Hochschule Hannover (Ed.), 13th Graduate School Days: 20/21 November 2020 / Stiftung Tierärztliche Hochschule Hannover (Zoo V 05). Stiftung Tierärztliche Hochschule Hannover.
Details anzeigen

Saletti, G., Gerlach, T., Jansen, J. M., Molle, A., Elbahesh, H., Ludlow, M., Li, W., Bosch, B.-J., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2020). Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63. Scientific Reports, 10: 21447. https://doi.org/10.1038/s41598-020-78506-9
Details anzeigen

Bergmann, S., & Elbahesh, H. (2019). Targeting the proviral host kinase, FAK, limits influenza a virus pathogenesis and NFkB-regulated pro-inflammatory responses. Virology, 534, 54–63. https://doi.org/10.1016/j.virol.2019.05.020
Details anzeigen